Glycation With Fructose: The Bitter Side of Nature's Own Sweetener.
Level 5 - mechanism / opinion, no new human data
Narrative mechanistic review with no original clinical or empirical data
PubMed 32013850 · doi:10.2174/1389450121666200204115751
What was done
Narrative review describing the biochemical pathways of non-enzymatic glycation by fructose (including Schiff base formation, Amadori rearrangement, and the generation of advanced glycation end products), endogenous fructose synthesis via the polyol pathway, dietary intake, and their potential pathophysiological consequences.
What was found
The abstract provides a qualitative mechanistic overview and reports no numerical data, effect sizes, or sample counts. It notes that fructose is highly reactive compared to glucose, generates structurally distinct glycation products, and can increase substantially in tissues with an active polyol pathway (e.g., ocular lens, peripheral nerves, erythrocytes, testis) during diabetes.
Why it matters
Highlights the biochemical mechanisms by which fructose-driven glycation and advanced glycation end products may contribute to diabetic, cardiovascular, and neurodegenerative complications.
Limits
The abstract describes a narrative review with no primary empirical data, no quantitative results, and no systematic search methodology. Claims are based on biochemical mechanism rather than controlled clinical trials or observational epidemiologic data.
Cited by
- supports Fructose is significantly sweeter than glucose because it binds more effectively to sweet taste receptors.